Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (51-60 of 724) with videos related to

Pageof 73
Sort By:
Cancer Treatment and Research|December 4, 2003
The role of systemic chemotherapy in the treatment of kidney cancerChristopher M George, Walter M Stadler
World Journal of Urology|May 26, 2001
Treatment of metastatic urothelial cancer in the post-MVAC eraE E Cohen, W M Stadler
Investigational New Drugs|June 1, 2000
Development of target-based antineoplastic agentsW M Stadler, M J Ratain
Praxis|December 16, 1998
[Hepatocellular carcinoma: interdisciplinary treatment concept]B M Stadler, K P Maier
Bollettino Della Societa Italiana Di Biologia Sperimentale|September 30, 1970
[Transformation stroboscopic movement as a method for measurement of the functional properties of "fragments" and "parts" in figural perception]G Trombini, M Stadler, L Stegagno
The Journal of Antibiotics|March 1, 1995
New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. IV. Structural elucidation of novel isocoumarin derivativesM Stadler, H Anke, O Sterner
Seminars in Oncology|February 1, 1995
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinomaW M Stadler, N J Vogelzang
Nature Clinical Practice. Oncology|September 1, 2005
Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer?Supriya G Mohile, Walter M Stadler
BJU International|April 20, 2007
Prognostic factors in localized renal cell cancerDavid A Knight, Walter M Stadler
Urological Research|January 1, 1996
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genesW M Stadler, O I Olopade
Pageof 73

Showing results (51-60 of 724) with videos related to

Sort By:
Pageof 73
Cancer Treatment and Research|December 4, 2003
The role of systemic chemotherapy in the treatment of kidney cancerChristopher M George, Walter M Stadler
World Journal of Urology|May 26, 2001
Treatment of metastatic urothelial cancer in the post-MVAC eraE E Cohen, W M Stadler
Investigational New Drugs|June 1, 2000
Development of target-based antineoplastic agentsW M Stadler, M J Ratain
Praxis|December 16, 1998
[Hepatocellular carcinoma: interdisciplinary treatment concept]B M Stadler, K P Maier
Bollettino Della Societa Italiana Di Biologia Sperimentale|September 30, 1970
[Transformation stroboscopic movement as a method for measurement of the functional properties of "fragments" and "parts" in figural perception]G Trombini, M Stadler, L Stegagno
The Journal of Antibiotics|March 1, 1995
New metabolites with nematicidal and antimicrobial activities from the ascomycete Lachnum papyraceum (Karst.) Karst. IV. Structural elucidation of novel isocoumarin derivativesM Stadler, H Anke, O Sterner
Seminars in Oncology|February 1, 1995
Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinomaW M Stadler, N J Vogelzang
Nature Clinical Practice. Oncology|September 1, 2005
Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer?Supriya G Mohile, Walter M Stadler
BJU International|April 20, 2007
Prognostic factors in localized renal cell cancerDavid A Knight, Walter M Stadler
Urological Research|January 1, 1996
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genesW M Stadler, O I Olopade
Pageof 73